<DOC>
	<DOCNO>NCT02393417</DOCNO>
	<brief_summary>This placebo-controlled , double-blind ( subject , Investigator , site staff exception unblinded dedicated staff handle study medication ) , phase 2a study 3 dose cohort , randomize ( conceal ) CANDIN placebo ( 3:1 ) . Main study 20 week ( 10 dos administer every week ) subject complete resolution injectable common wart . Subjects tolerate dose every 2 week due local tolerance issue may inject 3-week interval 10 dos , increase length study 29 week . Subjects follow 4 month final injection ( ) evidence new reoccurring wart safety evaluation .</brief_summary>
	<brief_title>Safety Efficacy Varying Regimens CANDIN Treatment Common Warts ( Verruca Vulgaris )</brief_title>
	<detailed_description />
	<mesh_term>Warts</mesh_term>
	<criteria>1 . Men woman age 18 65 year inclusively time consent 2 . Subjects present 3 20 injectable common wart ( verruca vulgaris ) least 12 week time Baseline Visit 3 . Subject 's common wart injection must measure 3 20 mm Baseline Visit locate hand , foot ( exclude sol ) , limb , and/or trunk . Flat , plantar , facial , periungual , genital wart wart region preexist inflammatory condition exclude injection 4 . Subjects enrol Cohort 3 must common wart injection least 2 different anatomical region define : left arm , right arm , leave hand , right hand , leave leg , right leg , leave foot ( exclude sole ) , right foot ( exclude sole ) torso 5 . Subject , male female willing use effective contraceptive method least 30 day Baseline Visit least 30 day last study drug administration unless childbearing potential define postmenopausal least 2 year ( female ) surgically sterile ( tubal ligation , oophorectomy , hysterectomy female , vasectomy male ) . The contraceptive use exception would individual exclusive sex partnership individual agree remain nonsexually active duration study . Acceptable contraceptive method subject include : Barrier method , condom , sponge diaphragm , combine spermicide foam , gel cream ; Hormonal contraception ( oral , intramuscular , implant transdermal include DepoProvera , Evra Nuvaring ) ; Intrauterine device ( IUD ) 6 . Mentally legally capable give informed consent prior study related procedure 1 . Presence systemic localized disease , condition , medication could interfere assessment safety efficacy compromise immune function include psoriasis 2 . Subject diagnosed diabetes mellitus 3 . Subject history keloid formation 4 . Injectable common wart ( ) locate area exist dermatologic condition ( psoriasis ) underlie inflammatory condition ( arthritic joint ) , tattoo implants/piercing/hardware marking may conceal response reaction exclude injection 5 . Existing/planned pregnancy , childbirth past six month prior Baseline Visit , breast feeding , plan donate eggs sperm study month follow last injection 6 . Treatment wart liquid nitrogen , carbon dioxide , electrodessication , laser , surgery , simple occlusion ( e.g . duct tape ) salicylic related acid , OTC treatment , cantharidin , treatment within 4 week Baseline Visit 7 . Treatment immunotherapy ( DPCP , DNCB ) , imiquimod , 5fluorouracil , bleomycin , podophyllin wart immunotherapy treatment design stimulate immune response ( except treatment already list exclusion criterion 6 ) within 12 week Baseline Visit 8 . Recalcitrant wart define successfully treat 5 treatment ( exclude OTC treatment ) 9 . Abnormal ( low &lt; 5 mm high &gt; 25 mm ) baseline result Delayed Type Hypersensitivity ( DTH ) test 10 . Subject condition treatment result immunocompromised 11 . Systemic treatment ( oral inject ) cimetidine , zinc supplement dose high 20 mg elemental zinc daily immunosuppressive drug ( : azathioprine , 6mercaptopurine , methotrexate , infliximab , adalimumab , etanercept , systemic steroid , etc . ) within 12 week Baseline Visit 12 . Subject use investigational agent within 30 day prior Baseline Visit within 5 halflives investigational agent prior Baseline Visit ( whichever longer ) 13 . Previous treatment wart type intralesional injection candida extract ( include CANDIN )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Verruca vulgaris</keyword>
	<keyword>Common Warts</keyword>
</DOC>